AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

ABVC · NASDAQ · Biotechnology

ABVC BioPharma (ABVC)

Botanical drug and vitreous-device developer using a partnership-led licensing model.

$0.8910

Pre-market+0.02 (+1.74%)

At close$0.8758(+6.11%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

	Insiders1 holder · as of Jul 12, 2022	2.97%	790.9K shares
	Otherremainder	97.03%	25.86M shares

26.65M company shares as of Sep 3, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
JiangInsider	2.97%	790,881	13Dfiled Jul 12, 2022 ↗
Lind Global Fund II LPInstitution	—9.90% of class, as filed	—	13Gfiled Aug 7, 2023 ↗
Tsung Shann Jiang¹Insiderdirector, officer: CSO and Director	4.54%	1.21M	Form 4filed Nov 15, 2021 ↗
Shuling Jiang²Insiderdirector, 10 percent owner	2.97%	790,881	Form 4filed Jul 12, 2022 ↗
Eugene Jiang¹Insiderdirector, officer: Chairman of the Board & CBO	0.27%	73,272	Form 4filed Nov 15, 2021 ↗
Yoshinobu Odaira³Insiderdirector	0.06%	16,370	Form 4filed Dec 10, 2021 ↗
Shin-Yu Miao¹Insiderdirector	0.03%	6,738	Form 4filed Nov 15, 2021 ↗
Howard Doong⁴Insiderofficer: Chief Executive Officer	0.01%	1,840	Form 4filed Nov 5, 2021 ↗
Chihliang An⁵Insiderofficer: Chief Financial Officer	0.01%	1,333	Form 4filed Mar 31, 2022 ↗
Tsang Ming Jiang⁶Insiderdirector	0.00%	607	Form 4filed Oct 26, 2021 ↗
Chang-Jen Jiang¹Insiderdirector	0.00%	595	Form 4filed Nov 15, 2021 ↗
Yen-Hsin Chou⁴Insiderdirector	0.00%	568	Form 4filed Nov 5, 2021 ↗
Chi-Hsin Richard King⁴Insiderofficer: Chief Scientific Officer	0.00%	87	Form 4filed Nov 5, 2021 ↗

Last filed Nov 15, 2021; leaving the company requires no filing. Not in the bar.
Last filed Jul 12, 2022; leaving the company requires no filing. Not in the bar.
Last filed Dec 10, 2021; leaving the company requires no filing. Not in the bar.
Last filed Nov 5, 2021; leaving the company requires no filing. Not in the bar.
Last filed Mar 31, 2022; leaving the company requires no filing. Not in the bar.
Last filed Oct 26, 2021; leaving the company requires no filing. Not in the bar.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Eugene Jiang	18.50%		13D	Jul 15, 2025 ↗

ABVC BioPharma (ABVC)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures